- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
Amrita Krishnan, MD, discusses how an ASH 2024 abstract from Sylvester Comprehensive Cancer Center suggests the potential of tocilizumab prophylaxis to mitigate cytokine release syndrome (CRS) in patients treated with bispecific therapies for multiple myeloma, and shares her approach to managing unique toxicities such as nail changes, skin reactions, and oral complications in patients receiving talquetamab.
EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management
EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond
EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
EP: 5.Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
EP: 6.Streamlining Transitions Between Academic and Community Centers
EP: 7.Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery
Video content above is prompted by the following:
- An ASH abstract from the group at Sylvester Comprehensive Cancer Center highlighted the potential of using tocilizumab prophylactically to mitigate CRS in patients treated with bispecific therapies for multiple myeloma. What are your thoughts on this approach, and how might it change current CRS prevention protocols?
- Talquetamab has unique toxicities such as nail changes, skin reactions, and oral complications. What are your recommendations for effectively managing these adverse events?
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
